News from annovis bio A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 22, 2023, 07:30 ET ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today...

Feb 08, 2023, 07:30 ET Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today...

Feb 01, 2023, 07:30 ET Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's and Parkinson's disease...

Jan 25, 2023, 07:30 ET ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today...

Jan 06, 2023, 07:30 ET Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today...

Nov 08, 2022, 17:35 ET Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today...

Oct 20, 2022, 07:30 ET Annovis Bio to Present at the 2022 ThinkEquity Investor Conference

(NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today...

Oct 11, 2022, 07:30 ET Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today ...

Oct 06, 2022, 07:30 ET Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases,...

Sep 29, 2022, 07:30 ET Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference

(NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today...

Sep 13, 2022, 07:30 ET Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases

(NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today...

Sep 08, 2022, 07:30 ET Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today ...

Aug 29, 2022, 16:00 ET Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced...

Aug 24, 2022, 07:30 ET Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases,...

Aug 08, 2022, 07:30 ET Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today...

Aug 01, 2022, 07:30 ET Annovis Bio to Participate on Alzheimer's Association International Conference Panel

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases,...

Jul 14, 2022, 07:30 ET Annovis Bio to Present at the Alzheimer's Association International Conference

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases,...

Jul 07, 2022, 07:30 ET Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases,...

Jun 09, 2022, 08:30 ET Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections

Annovis Bio (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today...

Sep 10, 2021, 09:00 ET Annovis Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD),...